This is the authors' abstract. We don't add key points for this paper.
Flaviviruses remain a formidable global health burden, necessitating therapeutic strategies that can overcome the inherent limitations and safety risks of traditional envelope-targeted approaches. Non-structural protein 1 (NS1) has emerged as a critical, multifunctional glycoprotein that orchestrates the viral life cycle and host pathogenesis. NS1 acts as a central hub for RNA replication intracellularly through essential interactions with the NS4A and NS4B proteins, while also regulating maturation of infectious progeny particles. Secreted NS1 (sNS1) functions as a potent virulence factor extracellularly that drives vascular leakage and immune evasion by directly disrupting the endothelial glycocalyx and antagonizing the complement system. Synthesizing current advances in NS1-targeted monoclonal antibodies has revealed a unique therapeutic capacity to circumvent antibody-dependent enhancement (ADE), while providing broad-spectrum protection across diverse flavivirus species. The synergistic mechanisms underlying sNS1 neutralization and Fc-mediated effector functions have been elucidated as a robust defense against established infection based on an analysis of representative antibodies, such as 1G5.3 and 2B7. Despite lingering translational hurdles regarding immune complex management, NS1-targeted strategies provide a safer and potentially transformative paradigm for the global prevention and control of flavivirus-associated diseases.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: